Trial | NCT00507169  Report issue

Title

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    None
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
Study Started
Sep 30
2006
Primary Completion
Sep 30
2007
Study Completion
Sep 30
2007
Last Update
Jun 08
2011
Estimate

Drug SVT-40776

Criteria 

Inclusion Criteria:

Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion Criteria:

Pregnant and breastfeeding women
Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)
No Results Posted